Diagnosis and management of rheumatoid arthritis; What is the current role of established and new imaging techniques in clinical practice?

Best Practice and Research: Clinical Rheumatology

Volumn 30, Issue 4, 2016, Pages 586-607

  D'Agostino, Maria Antonietta ^a,b   Haavardsholm, Espen A ^c   van der Laken, Conny J ^d  

^a HÔPITAL AMBROISE PARÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c DIAKONHJEMMET HOSPITAL   (Norway)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diagnostic and therapeutic evaluation; MRI; Optical imaging; PET imaging; Remission; Rheumatoid arthritis; Ultrasound

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CLINICAL EVALUATION; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; FLUORESCENCE IMAGING; HUMAN; MONITORING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOACOUSTICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; DIAGNOSTIC IMAGING; ECHOGRAPHY; PROCEDURES; X-RAY COMPUTED TOMOGRAPHY;

ARTHRITIS, RHEUMATOID; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 85000949465     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2016.10.011     Document Type: Review

References (174)

1. [1] Bridal, L., Lamuraglia, M., Physiscs of ultrasound. Wakefield, R.J., D'Agostino, M.A., (eds.) Essential applications of ultrasound in Rheumatology, 1st ed., July 2010, Elsevier.
2. Colebatch, A.N., Edwards, C.J., Østergaard, M., et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 72 (2013), 804–814.
3. [3] Rowbotham, E.L., Wakefield, R.J., Grainger, A.J., The technique and application of ultrasound in the diagnosis and management of inflammatory arthritis. Semin Musculoskelet Radiol 16 (2012), 360–366.
4. Nakagomi, D., Ikeda, K., Okubo, A., et al. Ultrasound can improve the accuracy of the 2010 American College of Rheumatology/European League against rheumatism classification criteria for rheumatoid arthritis to predict the requirement for methotrexate treatment. Arthritis Rheum 65 (2013), 890–898.
5. Nam, J.L., Hensor, E.M., Hunt, L., et al. Ultrasound findings predict progression to inflammatory arthritis in anti-CCP antibody-positive patients without clinical synovitis. Ann Rheum Dis, 2016, 10.1136/annrheumdis-2015-208235 Published Online First: 22 Jan 2016.
6. [6] Taylor, P.C., Steuer, A., Gruber, J., et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 50 (2004), 1107–1116.
7. [7] Naredo, E., Möller, I., Cruz, A., et al. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum 58 (2008), 2248–2256.
8. [8] Bøyesen, P., Haavardsholm, E.A., van der Heijde, D., et al. Prediction of MRI erosive progression: a comparison of modern imaging modalities in early rheumatoid arthritis patients. Ann Rheum Dis 70 (2011), 176–179.
9. [9] Fukae, J., Kon, Y., Henmi, M., et al. Change of synovial vascularity in a single finger joint assessed by power Doppler sonography correlated with radiographic change in rheumatoid arthritis: comparative study of a novel quantitative score with a semiquantitative score. Arthritis Care Res 62 (2010), 657–663.
10. [10] Funck-Brentano, T., Gandjbakhch, F., Etchepare, F., et al. Prediction of radiographic damage in early arthritis by sonographic erosions and power Doppler signal: a longitudinal observational study. Arthritis Care Res 65 (2013), 896–902.
11. [11] Dougados, M., Devauchelle-Pensec, V., Ferlet, J.F., et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis 72 (2013), 665–671.
12. [12] Macchioni, P., Magnani, M., Mulè, R., et al. Ultrasonographic predictors for the development of joint damage in rheumatoid arthritis patients: a single joint prospective study. Clin Exp Rheumatol 31 (2013), 8–17.
13. D'Agostino, M.A., Terslev, L., Wakefield, R., et al. Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission. Ann Rheum Dis 75 (2016), 1902–1908.
14. [14] Goekoop-Ruiterman, Y.P., de Vries-Bouwstra, J.K., Allaart, C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 58:2 Suppl (2008), S126–S135.
15. [15] Nell, V.P., Machold, K.P., Eberl, G., et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43 (2004), 906–914.
16. [16] Finckh, A., Liang, M.H., van Herckenrode, C.M., et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 55 (2006), 864–872.
17. [17] Aletaha, D., Neogi, T., Silman, A.J., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69 (2010), 1580–1588.
18. [18] Joshua, F., Edmonds, J., Lassere, M., Power Doppler ultrasound in musculoskeletal disease: a systematic review. Semin Arthritis Rheum 36 (2006), 99–108.
19. [19] Wakefield, R.J., Gibbon, W.W., Conaghan, P.G., et al. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 43 (2000), 2762–2770.
20. [20] Grassi, W., Filippucci, E., Farina, A., et al. Ultrasonography in the evaluation of bone erosions. Ann Rheum Dis 60 (2001), 98–103.
21. [21] Saraux, A., Berthelot, J.M., Chalès, G., et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 44 (2001), 2485–2491.
22. [22] Filer, A., de Pablo, P., Allen, G., et al. Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis. Ann Rheum Dis 70 (2011), 500–507.
23. [23] Wakefield, R.J., Green, M.J., Marzo-Ortega, H., et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis 63 (2004), 382–385.
24. [24] Rakieh, C., Nam, J.L., Hunt, L., et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis 74 (2015), 1659–1666.
25. [25] Freeston, J.E., Wakefield, R.J., Conaghan, P.G., et al. A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools. Ann Rheum Dis 69 (2010), 417–419.
26. [26] Stadt, L.A., Bos, W.H., Meursinge Reynders, M., et al. The value of ultrasonography in predicting arthritis in auto-antibody positive arthralgia patients: a prospective cohort study. Arthritis Res Ther, 12(3), 2010, R98.
27. [27] Witt, M., Mueller, F., Nigg, A., et al. Relevance of grade 1 gray-scale ultrasound findings in wrists and small joints to the assessment of subclinical synovitis in rheumatoid arthritis. Arthritis Rheum 65 (2013), 1694–1701.
28. Padovano, I., Costantino, F., Breban, M., et al. Prevalence of ultrasound synovial inflammatory findings in healthy subjects. Ann Rheum Dis 75 (2016), 1819–1823 Epub 2015 Nov 27.
29. [29] Terslev, L., Torp-Pedersen, S., Qvistgaard, E., et al. Effects of treatment with etanercept (Enbrel, TNRF: Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography. Ann Rheum Dis 62 (2003), 178–181.
30. [30] Albrecht, K., Grob, K., Lange, U., et al. Reliability of different Doppler ultrasound quantification methods and devices in the assessment of therapeutic response in arthritis. Rheumatology 47 (2008), 1521–1526.
31. [31] Naredo, E., Rodríguez, M., Campos, C., et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum 59 (2008), 515–522.
32. [32] Backhaus, M., Ohrndorf, S., Kellner, H., et al. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum 61 (2009), 1194–1201.
33. [33] Haavardsholm, E.A., Østergaard, M., Hammer, H.B., et al. Monitoring anti-TNFalpha treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage. Ann Rheum Dis 68 (2009), 1572–1579.
34. [34] Dougados, M., Jousse-Joulin, S., Mistretta, F., et al. Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. Ann Rheum Dis 69 (2010), 828–833.
35. [35] Hammer, H.B., Sveinsson, M., Kongtorp, A.K., et al. A 78-joints ultrasonographic assessment is associated with clinical assessments and is highly responsive to improvement in a longitudinal study of patients with rheumatoid arthritis starting adalimumab treatment. Ann Rheum Dis 69 (2010), 1349–1351.
36. [36] Larché, M.J., Seymour, M., Lim, A., et al. Quantitative power Doppler ultrasonography is a sensitive measure of metacarpophalangeal joint synovial vascularity in rheumatoid arthritis and declines significantly following a 2-week course of oral low-dose corticosteroids. J Rheumatol 37 (2010), 2493–2501.
37. [37] Hammer, H.B., Bolton-King, P., Bakkeheim, V., et al. Examination of intra and interrater reliability with a new ultrasonographic reference atlas for scoring of synovitis in patients with rheumatoid arthritis. Ann Rheum Dis 70 (2011), 1995–1998.
38. [38] Døhn, U.M., Ejbjerg, B., Boonen, A., et al. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis 70 (2011), 252–258.
39. [39] Perricone, C., Ceccarelli, F., Modesti, M., et al. The 6-joint ultrasonographic assessment: a valid, sensitive-to-change and feasible method for evaluating joint inflammation in RA. Rheumatology 51 (2012), 866–873.
40. [40] Damjanov, N., Radunovic, G., Prodanovic, S., et al. Construct validity and reliability of ultrasound disease activity score in assessing joint inflammation in RA: comparison with DAS-28. Rheumatology 51 (2012), 120–128.
41. [41] Seymour, M., Pétavy, F., Chiesa, F., et al. Ultrasonographic measures of synovitis in an early phase clinical trial: a double-blind, randomised, placebo and comparator controlled phase IIa trial of GW274150 (a selective inducible nitric oxide synthase inhibitor) in rheumatoid arthritis. Clin Exp Rheumatol 30 (2012), 254–261.
42. [42] Mandl, P., Balint, P.V., Brault, Y., et al. Clinical and ultrasound-based composite disease activity indices in rheumatoid arthritis: results from a multicenter, randomized study. Arthritis Care Res 65 (2013), 879–887.
43. D'Agostino, M.A., Wakefield, R.J., Berner-Hammer, H., et al. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. Ann Rheum Dis 75 (2016), 1763–1769 Epub 2015 Nov 20.
44. [44] Mandl, P., Balint, P.V., Brault, Y., et al. Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: results of a multicenter, randomized study. Arthritis Rheum 64 (2012), 1272–1282.
45. [45] Aga, A.B., Hammer, H.B., Olsen, I.C., et al. First step in the development of an ultrasound joint inflammation score for rheumatoid arthritis using a data-driven approach. Ann Rheum Dis, 2015, 10.1136/annrheumdis-2015-207572 Published Online First 17 June 2015.
46. [46] Aletaha, D., Ward, M.M., Machold, K.P., et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 52 (2005), 2625–2636.
47. [47] Molenaar, E.T.H., Voskuyl, A.E., Dinant, H.J., et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 50 (2004), 36–42.
48. [48] Markusse, I.M., Dirven, L., Gerards, A.H., et al. Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. Arthritis Res Ther, 17, 2015, 232.
49. [49] Ozgocmen, S., Ozdemir, H., Kiris, A., et al. Clinical evaluation and power Doppler sonography in rheumatoid arthritis: evidence for ongoing synovial inflammation in clinical remission. South Med J 101 (2008), 240–245.
50. [50] Saleem, B., Brown, A.K., Keen, H., et al. Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. Ann Rheum Dis 70 (2011), 792–798.
51. [51] Brown, A.K., Quinn, M.A., Karim, Z., et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 54 (2006), 3761–3773.
52. [52] Lillegraven, S., Prince, F.H., Shadick, N.A., et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 71 (2012), 681–686.
53. [53] Foltz, V., Gandjbakhch, F., Etchepare, F., et al. Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum 64 (2012), 67–76.
54. [54] Naredo, E., Valor, L., De la Torre, I., et al. Ultrasound joint inflammation in rheumatoid arthritis in clinical remission: how many and which joints should be assessed?. Arthritis Care Res 65 (2013), 512–517.
55. [55] Saleem, B., Brown, A.K., Keen, H., et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum 60 (2009), 1915–1922.
56. [56] Brown, A.K., Conaghan, P.G., Karim, Z., et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 58 (2008), 2958–2967.
57. [57] Scirè, C.A., Montecucco, C., Codullo, V., et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology 48 (2009), 1092–1097.
58. [58] Saleem, B., Brown, A.K., Quinn, M., et al. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis 71 (2012), 1316–1321.
59. [59] Naredo, E., Valor, L., De la Torre, I., et al. Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. Rheumatology 54 (2015), 1408–1414.
60. [60] Iwamoto, T., Ikeda, K., Hosokawa, J., et al. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res 66 (2014), 1576–1581.
61. [61] Kawashiri, S.Y., Nishino, A., Shimizu, T., et al. Ultrasound disease activity of bilateral wrist and finger joints at three months reflects the clinical response at six months of patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs. Mod Rheumatol, 2016 Sep 1, 1–5.
62. [62] Dale, J., Stirling, A., Zhang, R., et al. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann Rheum Dis 75 (2016), 1043–1050.
63. Haavardsholm, E.A., Aga, A.-B., Olsen, I.C., et al. Ultrasound in the management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ, 354, 2016, i4205.
64. [64] Klareskog, L., Catrina, A.I., Paget, S., Rheumatoid arthritis. Lancet 373 (2009), 659–672.
65. [65] Ostergaard, M., Peterfy, C., Conaghan, P., et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 30 (2003), 1385–1386.
66. [66] Sudol-Szopinska, I., Jurik, A.G., Eshed, I., et al. Recommendations of the ESSR arthritis subcommittee for the use of magnetic resonance imaging in musculoskeletal rheumatic diseases. Sem Musculoskelet Radiol 19 (2015), 396–411.
67. [67] Ejbjerg, B.J., Vestergaard, A., Jacobsen, S., et al. The smallest detectable difference and sensitivity to change of magnetic resonance imaging and radiographic scoring of structural joint damage in rheumatoid arthritis finger, wrist, and toe joints: a comparison of the OMERACT rheumatoid arthritis magnetic resonance imaging score applied to different joint combinations and the Sharp/van der Heijde radiographic score. Arthritis Rheum 52 (2005), 2300–2306.
68. Haavardsholm, E.A., Ostergaard, M., Ejbjerg, B.J., et al. Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetic resonance imaging score in a multireader, longitudinal setting. Arthritis Rheum 52 (2005), 3860–3867.
69. [69] Bird, P., Conaghan, P., Ejbjerg, B., et al. The development of the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis 64:Suppl. 1 (2005), i8–10.
70. [70] Conaghan, P., Bird, P., Ejbjerg, B., et al. The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: the metacarpophalangeal joints. Ann Rheum Dis 64:Suppl. 1 (2005), i11–21.
71. [71] Ejbjerg, B., McQueen, F., Lassere, M., et al. The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: the wrist joint. Ann Rheum Dis 64:Suppl. 1 (2005), i23–47.
72. [72] Ostergaard, M., Edmonds, J., McQueen, F., et al. An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis 64:Suppl. 1 (2005), i3–7.
73. [73] Haavardsholm, E.A., Ostergaard, M., Ejbjerg, B.J., et al. Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study. Ann Rheum Dis 66 (2007), 1216–1220.
74. [74] Ostergaard, M., Boyesen, P., Eshed, I., et al. Development and preliminary validation of a magnetic resonance imaging joint space narrowing score for use in rheumatoid arthritis: potential adjunct to the OMERACT RA MRI scoring system. J Rheumatol 38 (2011), 2045–2050.
75. [75] Dohn, U.M., Conaghan, P.G., Eshed, I., et al. The OMERACT-RAMRIS rheumatoid arthritis magnetic resonance imaging joint space narrowing score: intrareader and interreader reliability and agreement with computed tomography and conventional radiography. J Rheumatol 41 (2014), 392–397.
76. [76] Boers, M., Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 48 (2003), 1771–1774.
77. [77] Sharp, J.T., Speculations on why early treatment of rheumatoid arthritis is uniquely effective. J Rheumatol 35 (2008), 2090–2093.
78. [78] Szkudlarek, M., Narvestad, E., Klarlund, M., et al. Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination. Arthritis Rheum 50 (2004), 2103–2112.
79. [79] Tamai, M., Kawakami, A., Iwamoto, N., et al. Comparative study of the detection of joint injury in early-stage rheumatoid arthritis by magnetic resonance imaging of the wrist and finger joints and physical examination. Arthritis Care Res Hob 63 (2011), 436–439.
80. [80] Sugimoto, H., Takeda, A., Masuyama, J., et al. Early-stage rheumatoid arthritis: diagnostic accuracy of MR imaging. Radiology 198 (1996), 185–192.
81. [81] Sugimoto, H., Takeda, A., Hyodoh, K., Early-stage rheumatoid arthritis: prospective study of the effectiveness of MR imaging for diagnosis. Radiology 216 (2000), 569–575.
82. [82] Narvaez, J., Sirvent, E., Narvaez, J.A., et al. Usefulness of magnetic resonance imaging of the hand versus anticyclic citrullinated peptide antibody testing to confirm the diagnosis of clinically suspected early rheumatoid arthritis in the absence of rheumatoid factor and radiographic erosions. Semin Arthritis Rheum 38 (2008), 101–109.
83. [83] Duer, A., Ostergaard, M., Horslev-Petersen, K., et al. Magnetic resonance imaging and bone scintigraphy in the differential diagnosis of unclassified arthritis. Ann Rheum Dis 67 (2008), 48–51.
84. [84] Duer-Jensen, A., Horslev-Petersen, K., Hetland, M.L., et al. Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis. Arthritis Rheum 63 (2011), 2192–2202.
85. [85] Huang, J., Stewart, N., Crabbe, J., et al. A 1-year follow-up study of dynamic magnetic resonance imaging in early rheumatoid arthritis reveals synovitis to be increased in shared epitope-positive patients and predictive of erosions at 1 year. Rheumatol Oxf Engl 39 (2000), 407–416.
86. [86] McQueen, F.M., Benton, N., Perry, D., et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 48 (2003), 1814–1827.
87. [87] Haavardsholm, E.A., Boyesen, P., Ostergaard, M., et al. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 67 (2008), 794–800.
88. [88] Boyesen, P., Haavardsholm, E.A., Ostergaard, M., et al. MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis 70 (2011), 428–433.
89. [89] Lindegaard, H.M., Vallo, J., Horslev-Petersen, K., et al. Low-cost, low-field dedicated extremity magnetic resonance imaging in early rheumatoid arthritis: a 1-year follow-up study. Ann Rheum Dis 65 (2006), 1208–1212.
90. [90] McQueen, F.M., Stewart, N., Crabbe, J., et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 58 (1999), 156–163.
91. [91] Savnik, A., Malmskov, H., Thomsen, H.S., et al. MRI of the wrist and finger joints in inflammatory joint diseases at 1-year interval: MRI features to predict bone erosions. Eur Radiol 12 (2002), 1203–1210.
92. [92] Tanaka, N., Sakahashi, H., Ishii, S., et al. Synovial membrane enhancement and bone erosion by magnetic resonance imaging for prediction of radiologic progression in patients with early rheumatoid arthritis. Rheumatol Int 25 (2005), 103–107.
93. [93] Hetland, M.L., Ejbjerg, B., Horslev-Petersen, K., et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 68 (2009), 384–390.
94. [94] Hetland, M.L., Stengaard-Pedersen, K., Junker, P., et al. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 69 (2010), 1789–1795.
95. [95] Ranganath, V.K., Motamedi, K., Haavardsholm, E.A., et al. Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy. Arthritis Care Res Hob 67 (2015), 929–939.
96. [96] Ostergaard, M., Jacobsson, L.T., Schaufelberger, C., et al. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Ann Rheum Dis 74 (2015), 1156–1163.
97. [97] Axelsen, M.B., Eshed, I., Horslev-Petersen, K., et al. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Ann Rheum Dis 74 (2015), 867–875.
98. [98] Bensaoud, N., Rostom, S., Bahiri, R., et al. Efficacy of tocilizumab on MRI-determined bone oedema in rheumatoid arthritis. Clin Rheumatol 34 (2015), 1031–1037.
99. [99] Conaghan, P.G., Ostergaard, M., Bowes, M.A., et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis 75 (2016), 1024–1033.
100. Baker, J.F., Conaghan, P.G., Emery, P., et al. Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis. Ann Rheum Dis 75 (2016), 1114–1119.
101. [101] Peterfy, C., Burmester, G.R., Bykerk, V.P., et al. Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Ann Rheum Dis 75 (2016), 1501–1505 [Epub 2016 Feb 10].
102. [102] Conaghan, P.G., Durez, P., Alten, R.E., et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis 72 (2013), 1287–1294.
103. [103] Peterfy, C., Ostergaard, M., Conaghan, P.G., MRI comes of age in RA clinical trials. Ann Rheum Dis 72 (2013), 794–796.
104. [104] Peterfy, C.G., Olech, E., DiCarlo, J.C., et al. Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). Arthritis Res Ther, 15, 2013, R44.
105. [105] Felson, D.T., Smolen, J.S., Wells, G., et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63 (2011), 573–586.
106. [106] Gandjbakhch, F., Foltz, V., Mallet, A., et al. Bone marrow oedema predicts structural progression in a 1-year follow-up of 85 patients with RA in remission or with low disease activity with low-field MRI. Ann Rheum Dis 70 (2011), 2159–2162.
107. [107] Gandjbakhch, F., Conaghan, P.G., Ejbjerg, B., et al. Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. J Rheumatol 38 (2011), 2039–2044.
108. [108] Haavardsholm, E.A., Lie, E., Lillegraven, S., Should modern imaging be part of remission criteria in rheumatoid arthritis?. Best Pract Res Clin Rheumatol 26 (2012), 767–785.
109. [109] Ostergaard, M., Moller-Bisgaard, S., Rheumatoid arthritis: is imaging needed to define remission in rheumatoid arthritis?. Nat Rev Rheumatol 10 (2014), 326–328.
110. [110] Moller-Bisgaard, S., Horslev-Petersen, K., Ejbjerg, B.J., et al. Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial. Trials, 16, 2015, 178.
111. [111] Phelps, M.E., PET – molecular imaging and its biological applications. 2004, Springer, New York.
112. [112] Palmer, W.E., Rosenthal, D.I., Schoenberg, O.I., et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 196 (1995), 647–655.
113. [113] Beckers, C., Ribbens, C., Andre, B., et al. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Nucl Med 45 (2004), 956–964.
114. [114] Kubota, K., Ito, K., Morooka, M., et al. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med 23 (2009), 783–791.
115. [115] Goerres, G.W., Forster, A., Uebelhart, D., et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med 31 (2006), 386–390.
116. Elzinga, E.H., van der Laken, C.J., Comans, E.F., et al. 2-Deoxy-2-[F-18]fluoro-D-glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis. Mol Imaging Biol 9 (2007), 357–360.
117. [117] Houseni, M., Chamroonrat, W., Zhuang, H., et al. Facet joint arthropathy demonstrated on FDG-PET. Clin Nucl Med 31 (2006), 418–419.
118. [118] von Schulthess, G.K., Meier, N., Stumpe, K.D., Joint accumulations of FDG in whole body PET scans. Nukl Med 40 (2001), 193–197.
119. [119] Wandler, E., Kramer, E.L., Sherman, O., et al. Diffuse FDG shoulder uptake on PET is associated with clinical findings of osteoarthritis. AJR Am J Roentgenol 185 (2005), 797–803.
120. [120] Taniguchi, Y., Arii, K., Kumon, Y., et al. Positron emission tomography/computed tomography: a clinical tool for evaluation of enthesitis in patients with spondyloarthritides. Rheumatology 49 (2010), 348–354.
121. [121] Okabe, T., Shibata, H., Shizukuishi, K., et al. F-18 FDG uptake patterns and disease activity of collagen vascular diseases-associated arthritis. Clin Nucl Med 36 (2011), 350–354.
122. [122] Miese, F., Scherer, A., Ostendorf, B., et al. Hybrid 18F-FDG PET-MRI of the hand in rheumatoid arthritis: initial results. Clin Rheumatol 30 (2011), 1247–1250.
123. [123] Roivainen, A., Parkkola, R., Yli-Kerttula, T., et al. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 48 (2003), 3077–3084.
124. [124] Jahangier, Z.N., Jacobs, J.W., Kraan, M.C., et al. Pretreatment macrophage infiltration of the synovium predicts the clinical effect of both radiation synovectomy and intra-articular glucocorticoids. Ann Rheum Dis 65 (2006), 1286–1292.
125. van der Laken, C.J., Elzinga, E.H., Kropholler, M.A., et al. Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum 58 (2008), 3350–3355.
126. [126] Gent, Y.Y., Weijers, K., Molthoff, C.F., et al. Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis. Arthritis Res Ther, 16, 2014, R70.
127. 1⁸F]DPA-714 as a biomarker for positron emission tomography imaging of rheumatoid arthritis in an animal model. Arthritis Res Ther, 16, 2014, R69.
128. [128] Van der Heijden, J.W., Oerlemans, R., Dijkmans, B.A.C., et al. Folate receptor-β as potential delivery route for novel folate antagonists to macrophages in synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 60 (2009), 12–21.
129. [129] Matteson, E.L., Lowe, V.J., Prendergast, F.G., et al. Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. Clin Exp Rheumatol 27 (2009), 253–259.
130. [130] Gent, Y.Y., Weijers, K., Molthoff, C.F., et al. Evaluation of the novel folate receptor ligand [18F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. Arthritis Res Ther, 15(2), 2013, R37.
131. [131] Virtanen, H., Autio, A., Siitonen, R., et al. 68Ga-DOTA-Siglec-9-a new imaging tool to detect synovitis. Arthritis Res Ther, 17, 2015, 308.
132. [132] Zhu, Z., Yin, Y., Zheng, K., et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using ⁶⁸Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study. Ann Rheum Dis 73 (2014), 1269–1272 Laverman P, van der Geest T, Terry SY, et al. Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis. J Nucl Med. 2015;56:778-783.
133. [133] Watanabe, T., Takase-Minegishi, K., Ihata, A., et al. (18)F-FDG and (18)F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis. Mod Rheumatol 26 (2016), 180–187.
134. [134] Khairnar, A., Marchand, F., Vidal, A., et al. 99mTc-NTP 15-5 imaging for cartilage involvement in experimental rheumatoid arthritis: comparison with routinely used molecular imaging methods and sensitivity to chronic nonsteroidal antiinflammatory drug treatment. J Nucl Med 56 (2015), 798–804.
135. [135] Bos, W.H., Wolbink, G.J., Boers, M., et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 69 (2010), 490–494.
136. [136] de Bois, M.H., Arndt, J.W., Speyer, I., et al. Technetium-99m labelled human immunoglobulin scintigraphy predicts rheumatoid arthritis in patients with arthralgia. Scand J Rheumatol 25 (1996), 155–158.
137. [137] Gent, Y.Y.J., Voskuyl, A.E., Kloet, R.W., et al. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study. Arthritis Rheum 64 (2012), 62–66.
138. [138] Conti, F., Malviya, G., Ceccarelli, F., et al. Role of scintigraphy with (99m)Tc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis. Eur J Nucl Med Mol Imaging 39 (2012), 1339–1347.
139. van der Laken, C.J., Voskuyl, A.E., Roos, J.C., et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 66 (2007), 253–256.
140. [140] Polisson, R.P., Schoenberg, O.I., Fischman, A., et al. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum 38 (1995 Jun), 819–825.
141. [141] Danfors, T., Bergström, M., Feltelius, N., et al. Positron emission tomography with 11C-D-deprenyl in patients with rheumatoid arthritis. Evaluation of knee joint inflammation before and after intra-articular glucocorticoid treatment. Scand J Rheumatol 26 (1997), 43–48.
142. [142] Beckers, C., Jeukens, X., Ribbens, C., et al. (18)F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging 33 (2006), 275–280.
143. [143] Gent, Y.Y., Ahmadi, N., Voskuyl, A.E., et al. Detection of subclinical synovitis with macrophage targeting and positron emission tomography in patients with rheumatoid arthritis without clinical arthritis. J Rheumatol 41 (2014), 2145–2152 Gent YY, Ter Wee MM, Voskuyl AE, et al. Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study. Arthritis Res Ther 2015 Sep 25;17:266.
144. [144] Elzinga, E.H., van der Laken, C.J., Comans, E.F., et al. 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med 52 (2011), 77–80.
145. [145] Roivainen, A., Hautaniemi, S., Möttönen, T., et al. Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs. Eur J Nucl Med Mol Imaging 40 (2013), 403–410.
146. [146] Hielscher, A.H., Klose, A.D., Scheel, A.K., et al. Saggital laer optical tomography for imaging of reumatoid finger joints. Phys Med Biol 49 (2004), 1147–1163.
147. [147] Scheel, A.K., Backhaus, M., Klose, A.D., et al. First clinical evaluation of sagittal laser optical tomography for detection of synovitis in arthritic finger joints. Ann Rheum Dis 64 (2005), 239–245.
148. [148] Scheel, A.K., Krause, A., Rheinbaben, I.M., et al. Assessment of proximal finger joint inflammation in patients with rheumatoid arthritis, using a novel laser-based imaging technique. Arthritis Rheum 46 (2002), 1177–1184.
149. [149] Amitai, I., Werner, S., Schicke, B., et al. Comparison of photo optical imaging with musculoskeletal ultrasound and clinical examination in the assessment of inflammatory activity in proximal interphalangeal joints in rheumatoid arthritis and osteoarthritis. J Rheumatol 42 (2015), 1595–1602.
150. [150] van Onna, M., Ten Cate, D.F., Tsoi, K.L., et al. Assessment of disease activity in patients with rheumatoid arthritis using optical spectral transmission measurements, a non-invasive imaging technique. Ann Rheum Dis 75 (2016), 511–518.
151. [151] Fischer, T., Ebert, B., Voigt, J., et al. Detection of rheumatoid arthritis using non-specific contrast enhanced fluorescence imaging. Acad Radiol 17 (2010), 375–381.
152. [152] Werner, S.G., Langer, H.E., Ohrndorf, S., et al. Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology. Ann Rheum Dis 71 (2012), 504–510.
153. [153] Mohajerani, P., Koch, M., Thürmel, K., et al. Fluorescence-aided tomographic imaging of synovitis in the human finger. Radiology 272 (2014), 865–874.
154. [154] Glimm, A.M., Werner, S.G., Burmester, G.R., et al. Analysis of distribution and severity of inflammation in patients with osteoarthitis compared to rheumatoid arthritis by ICG-enhanced fluorescence optical imaging and musculoskeletal ultrasound: a pilot study. Ann Rheum Dis 75 (2016), 566–570.
155. [155] Kisten, Y., Györi, N., Af Klint, E., et al. Detection of clinically manifest and silent synovitis in the hands and wrists by fluorescence optical imaging. RMD Open, 1, 2015, e000106.
156. [156] Krohn, M., Ohrndorf, S., Werner, S.G., et al. Near-infrared fluorescence optical imaging in early rheumatoid arthritis: a comparison to magnetic resonance imaging and ultrasonography. J Rheumatol 42 (2015), 1112–1118.
157. [157] Meier, R., Thuermel, K., Noël, P.B., et al. Synovitis in patients with early inflammatory arthritis monitored with quantitative analysis of dynamic contrast-enhanced optical imaging and MR imaging. Radiology 270 (2014), 176–185.
158. [158] Fischer, T., Gemeinhardt, I., Wagner, S., et al. Assessment of unspecific near-infrared dyes in laser-induced fluorescence imaging of experimental arthritis. Acad Radiol 13 (2006), 4–13.
159. [159] Hansch, A., Frey, O., Hilger, I., et al. Diagnosis of arthritis using near-infrared fluorochrome Cy5.5. Invest Radiol 39 (2004), 626–632.
160. [160] Vollmer, S., Gemeinhardt, I., Vater, A., et al. In vivo therapy monitoring of experimental rheumatoid arthritis in rats using near-infrared fluorescence imaging. J Biomed Opt, 19, 2014, 36011.
161. [161] Hansch, A., Frey, O., Sauner, D., et al. In vivo imaging of experimental arthritis with near-infrared fluorescence. Arthritis Rheum 50 (2004), 961–967.
162. [162] Chen, W.T., Mahmood, U., Weissleder, R., et al. Arthritis imaging using a near-infrared fluorescence folate-targeted probe. Arthritis Res Ther 7 (2005), R310–R317.
163. [163] Gompels, L.L., Madden, L., Lim, N.H., et al. In vivo fluorescence imaging of E-selectin: quantitative detection of endothelial activation in a mouse model of arthritis. Arthritis Rheum 63 (2011), 107–117.
164. [164] Qi, X., Flick, M.J., Frederick, M., et al. Saposin C coupled lipid nanovesicles specifically target arthritic mouse joints for optical imaging of disease severity. PLoS One, 7, 2012, e33966.
165. [165] Zhang, S., Shao, P., Ling, X., et al. In vivo inflammation imaging using a CB2R-targeted near infrared fluorescent probe. Am J Nucl Med Mol Imaging 5 (2015), 246–258.
166. [166] Vogl, T., Eisenblatter, M., Voller, T., et al. Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity. Nat Commun, 5, 2014, 4593.
167. [167] Lanzardo, S., Conti, L., Brioschi, C., et al. A new optical imaging probe targeting αVβ3 integrin in glioblastoma xenografts. Contrast Media Mol Imaging 6 (2011), 449–458.
168. [168] Peterson, J.D., Labranche, T.P., Vasquez, K.O., et al. Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis. Arthritis Res Ther, 12, 2010, R105.
169. [169] Gabriel, D., Lange, N., Chobaz-Peclat, V., et al. Thrombin-sensitive dual fluorescence imaging and therapeutic agent for detection and treatment of synovial inflammation in murine rheumatoid arthritis. Control Release 163 (2012), 178–186.
170. [170] Wunder, A., Tung, C.H., Muller-Ladner, U., et al. In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. Arthritis Rheum 50 (2004), 2459–2465.
171. [171] Lai, W.F., Chang, C.H., Tang, Y., et al. Early diagnosis of osteoarthritis using cathepsin B sensitive near-infrared fluorescent probes. Osteoarthr Cartil 12 (2004), 239–244.
172. [172] Chamberland, D.L., Wang, X., Roessler, B.J., Photoacoustic tomography of carrageenan-induced arthritis in a rat model. J Biomed Opt, 13, 2008, 011005.
173. [173] Wang, X., Chamberland, D.L., Jamadar, D.A., Noninvasive photo acoustic tomography of human peripheral joints toward diagnosis of inflammatory arthritis. Opt Lett 32 (2007), 3002–3004.
174. [174] Xu, G., Rajian, J.R., Girish, G., et al. Photoacoustic and ultrasound dual-modality imaging of human peripheral joints. J Biomed Opt, 18, 2013, 10502.